May 13, 2014
Rabia Tassaduq, a candidate for the Master of Public Health degree from the New York University Global Institute of Public Health (NYU GIPH), will present the preliminary findings of a semester-long project during the NYU GIPH Capstone and Internship Symposium on Monday, May 19th. The project, which was initiated by Dr. Mark Wolff, Chair of Cariology and Comprehensive Care at NYU College of Dentistry, sought to evaluate the acceptability and validity of a photograph of the eye as a screening method for identifying pre-diabetics/diabetics in a dental setting.
It is estimated that 25.8 million individuals in the US suffer from diabetes mellitus, and that 7 million of these individuals are undiagnosed. Diabetes increases the incidence and severity of negative oral health outcomes such as gum disease, tooth loss and post-surgical complications, and knowledge of the diabetes status of patients could greatly influence the course of dental treatment. Although quick testing of HbA1c (average blood sugar levels over the past 3 months) utilizing chair-side analysis of non-fasting, finger stick blood is both possible and economical, few dental practitioners have adopted this practice. The purpose of this project is to determine the acceptability and validity of an alternative to the HbA1c test – a photograph of the microvasculature of the eye. It has been established that the microvascular complications, specifically microangiopathy, in the bulbar conjunctiva of patients can be utilized to identify patients with type-2 diabetes mellitus. This method would likely provide increased ease of use, increased patient comfort, and lower costs associated with the test.
Although data analysis for the project is still ongoing, preliminary analysis shows that subjects expressed a high willingness to have the photograph procedure performed in a dental setting.
Rabia Tassaduq received a Bachelor of Dental Surgery from the Army Medical College, National University of Sciences and Technology in Pakistan, and received a Fulbright Scholarship to study at the NYU GIPH. She plans to obtain a PhD in epidemiology and pursue a career in research and academia. Rabia became interested in public health during her dental residency, when she realized that population-scale public health measures are necessary to truly have an impact on overall disease burden and its human, social and economic effects. She feels that “research … is an essential component because it helps us to both identify what the population needs are, and also to test various treatment modalities in order to determine the most effective method of solving health-related problems in the population.” Rabia was mentored by Dr. Patricia Corby, Associate Director of the Bluestone Center for Clinical Research, during her internship.
NYU GIPH Capstone and Internship Symposium
Date: Monday, May 19, 2014
Time: 5:30 pm
Location: NYU Kimmel Center, Rosenthal Pavilion
60 Washington Square South, New York, NY
About the NYU Global Institute of Public Health-- The NYU Global Institute of Public Health crosses disciplinary boundaries to address the world’s most pressing health problems. Drawing from resources across NYU’s schools, the Institute delivers truly interdisciplinary public health education at the undergraduate, master’s and doctoral level. The Institute also supports cutting-edge and collaborative research on public health issues around the world. The GIPH builds on the global reach of NYU’s unique Global Network University; draws strength from the entrepreneurial spirit of NYU’s many talented faculty and students; and serves as a conduit for groundbreaking research and education that advances and promotes equitable health for all.
About the Bluestone Center for Clinical Research--The Bluestone Center for Clinical Research, in conjunction with the NYU Oral Cancer Center, is an academic research organization located at the NYU College of Dentistry. Bluestone’s mission is to take a creative scientific approach to transform world health. Bluestone is dedicated to conducting research in oral cancer, cancer symptomology, pharmaceuticals, medical devices, emerging biotechnology, periodontics, implants, and oral health products.